AMENDMENT NO. 1 TO LICENCE OF TECHNOLOGY AGREEMENT
Exhibit 10.2
AMENDMENT NO. 1 TO LICENCE OF TECHNOLOGY AGREEMENT
This Amendment No. 1 to the Agreement (this “Amendment”), effective as of 12th February 2021 (the “Amendment Effective Date”), is made by and between Oxford University Innovation Limited (Company Registration No. 2199542) whose registered office is a University Offices, Wellington Square, Oxford OX1 2JD, England (“OUI”); Medical Research Council, as part of United Kingdom Research and Innovation (also known as UK Research and Innovation) a body corporate established pursuant to section 91 of the Higher Education and Research Act 2017 whose address is Polaris House, North Star Xxxxxx, Xxxxxxx XX0 0XX, Xxxxxx Xxxxxxx (“MRC”); and PepGen Limited (Company Registration No. 11170794) whose registered office is at Bioescalator, Innovation Building, The Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ (the “Licensee”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
BACKGROUND
WHEREAS, OUI, MRC and Licensee are parties to a certain Licence of Technology Agreement, dated 23 November 2020 (the “Agreement”);
WHEREAS, OUI, MRC and Licensee wish to update the schedules of “Applications” and “Inventors” listed on Schedule 2 of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, OUI, MRC and Licensee agree as follows:
“(7) For OUI project number 18634/(MRC Project 2022-001), PCT/GB2021/050357, filed 12th February 2021, entitled “Cell-penetrating peptides and methods of their use” and progeny thereof.
(8) For OUI project number 18634/(MRC Project 2022-001), PCT/GB2022/050371, filed 11th February 2022, entitled “Cell-penetrating peptides and methods of their use” and progeny thereof.”
Application |
Oxford Inventors |
MRC Inventors |
Paris Inventors |
7 |
Prof Xxxxxxx Xxxx Xx Xxxxxx Xxxxxxx |
Xx Xxxxxxx Xxxx
Dr Xxxxxx Xxxxxxxx |
|
Exhibit 10.2
DocuSign Envelope ID: 44C38892-0D57-47FB-B310-0E5CBECEC354
CONFIDENTIAL
|
Xx Xxxxxxxx Xxxxxxx Xx Xxxxxx XxXxxxxx Xx Xxxxxxx Xxx
Xx Xxxxxxx Xxxxxxx
Xx Xxxxxx Xxxxxx Xx Xxxxxxx Xxxxx Xx Xxxxxxxxx Xxxxxxxx |
Xx Xxx X’Xxxxxxx |
|
8 |
Prof Xxxxxxx Xxxx Xx Xxxxxx Xxxxxxx
Xx Xxxxxxxx Xxxxxxx
Xx Xxxxxx XxXxxxxx
Xx Xxxxxxx Xxx Xx Xxxxxxx Xxxxxxx Xx Xxxxxx Xxxxxx
Xx Xxxxxxx Xxxxx Xx Xxxxxxxxx |
Xx Xxxxxxx Xxxx Dr Xxxxxx Xxxxxxxx Xx Xxx X’Xxxxxxx |
|
2
ACTIVE/115150924.1
DocuSign Envelope ID: 44C38892-0D57-47FB-B310-0E5CBECEC354
CONFIDENTIAL
|
Xxxxxxxx |
|
|
3
ACTIVE/115150924.1
DocuSign Envelope ID: 44C38892-0D57-47FB-B310-0E5CBECEC354
CONFIDENTIAL
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
ACTIVE/115150924.1
DocuSign Envelope ID: 44C38892-0D57-47FB-B310-0E5CBECEC354
CONFIDENTIAL
IN WITNESS WHEREOF, this Amendment is executed by the duly authorized representatives of the parties.
Date: February 11, 2022 |
By: |
/s/ Xxxxx Xxxxx |
|
|
Xxxxx Xxxxx |
|
|
Chief Operating Officer |
|
|
|
Date: February 11, 2022 |
By: |
/s/ Xxxx Xxxxxxx |
|
|
Xxxx Xxxxxxx |
|
|
Authorized Signatory of United Kingdom Research and Innovation |
|
|
|
Date: February 11, 2022 |
By: |
/s/ Xxxxx XxXxxxxx |
|
|
Xxxxx XxXxxxxx |
|
|
Director, PepGen Limited |
ACTIVE/115150924.1